R
Richard Bucala
Researcher at Yale University
Publications - 622
Citations - 58697
Richard Bucala is an academic researcher from Yale University. The author has contributed to research in topics: Macrophage migration inhibitory factor & Cytokine. The author has an hindex of 119, co-authored 595 publications receiving 54607 citations. Previous affiliations of Richard Bucala include École Polytechnique Fédérale de Lausanne & Rockefeller University.
Papers
More filters
Journal ArticleDOI
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
Gil Benedek,Gil Benedek,Roberto Meza-Romero,Roberto Meza-Romero,Shayne Andrew,Shayne Andrew,Lin Leng,Gregory G. Burrows,Dennis Bourdette,Halina Offner,Halina Offner,Richard Bucala,Arthur A. Vandenbark +12 more
TL;DR: In this article, partial MHC class II constructs comprised of linked β1α1 domains with covalently attached antigenic peptides (also referred to as recombinant T-cell receptor ligands - RTLs) were shown to inhibit MIF activity by not only blocking the binding of rhMIF to immunopurified CD74, but also down-regulating CD74 cell-surface expression.
Journal ArticleDOI
A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease.
TL;DR: Functional promoter polymorphisms in the MIF gene influence plasma MIF levels in AOSd and may contribute to disease susceptibility or clinical presentation of AOSD.
Journal ArticleDOI
Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4.
Ming Zhang,Chun-Mei Wang,Jing Li,Zhaojie Meng,Shengnan Wei,Ji Li,Richard Bucala,Yu-Lin Li,Li Chen +8 more
TL;DR: In this paper, the authors investigated the effect of berberine on palmitate-induced endothelial dysfunction in human umbilical vein endothelial cells (HUVECs).
Journal ArticleDOI
Receptor agonists of macrophage migration inhibitory factor.
William L. Jorgensen,Sunilkumar Gandavadi,Xin Du,Alissa A. Hare,Alexander Trofimov,Lin Leng,Richard Bucala +6 more
TL;DR: The structure-based molecular design has led to the discovery of not only antagonists, but also the first agonists of MIF-CD74 binding, which contain a triazole core that is readily assembled via Cu-catalyzed click chemistry.
Journal ArticleDOI
Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.
Leona Mawhinney,Leona Mawhinney,Michelle E. Armstrong,Ciaran O’Reilly,Richard Bucala,Lin Leng,Gunter Fingerle-Rowson,Darren Fayne,Michael P. Keane,Aisling Tynan,Lewena Maher,Gordon Cooke,David Lloyd,Helen Conroy,Seamas C. Donnelly +14 more
TL;DR: A novel inhibitor is identified that blocks the hydrophobic pocket of MIF, which houses its specific tautomerase enzymatic activity, and it is demonstrated that targeting this unique active site significantly attenuates lung cancer growth in in vitro and in vivo systems.